Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099918 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 717
- Enrollment target
NCT00099918 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 717 participants.
The verdict
NCT00099918, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 717 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
Interventions
- DRUG vildagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099918
The ClinicalTrials.gov registry entry for NCT00099918 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vildagliptin is the first listed.
NCT00099918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099918 about?
NCT00099918 is a clinical study titled "Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes". The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
What is the current status of trial NCT00099918?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 717 participants. The study started on 2004-05. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00099918?
The interventions under investigation include: vildagliptin (DRUG).
Who is sponsoring clinical trial NCT00099918?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.